NorthWest Biotherapeutics Inc (NWBO)

[Adam_Feuerstein]

Again, you're mistaken.

The Agenus (Antigenics, previously) cancer "vaccine" platform has been marred with clinical trail failure.

Oncophage (now known as Prophage) failed pivotal trials in ovarian cancer and melanoma. Despite the negative studies, Antigenics tried to get Oncophage approved in Europe. Regulators there rejected them. The FDA told Antigenics that it couldn't file for approval in the US.

Prophage data in GBM to date comes from a single arm study, which is essentially meaningless, just as the NWBO DcVax studies done by Linda Liau are meaningless due to lack of comparator arm.

I guess you could hold out some hope that the ongoing Prophage randomized study in GBM might show something positive, but it's hard to be confident given the past failures.

Agenus, itself, barely focuses investor attention on Prophage any more. The company is much more interested in its other cancer immunotherapy compounds.